

Temporary benefits added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of the following products, ACH-Olmesartan HCTZ 20 mg/12.5 mg Tablet (DIN 02468948) manufactured by Accord Healthcare Inc, will be considered as a temporary benefit for the *ADBL*.

DIN	Product Description	Manufacturer
02443112	Act Olmesartan HCT 20 mg/12.5 mg Tablet	Actavis Pharma Company
02453606	Apo-Olmesartan/HCTZ 20 mg/12.5 mg Tablet	Apotex Inc.
02319616	Olmetec Plus 20 mg/12.5 mg Tablet	Merck Canada Inc.

As of **July 23, 2019**, all claims for ACH-Olmesartan HCTZ 20 mg/12.5 mg Tablet (DIN 02468948), available direct through the manufacturer, will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at ab.bluecross.ca/providers/pharmacy-home.html.

If this situation continues to be a long-term matter, then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

Due to the unavailability of the following products, ACH-Olmesartan HCTZ 40 mg/25 mg Tablet (DIN 02468964) manufactured by Accord Healthcare Inc, will be considered as a temporary benefit for the *ADBL*.

DIN	Product Description	Manufacturer
02443139	Act Olmesartan HCT 40 mg/25 mg Tablet	Actavis Pharma Company
02453622	Apo-Olmesartan HCT 40 mg/25 mg Tablet	Apotex Inc.
02319632	Olmetec Plus 40 mg/25 mg Tablet	Merck Canada Inc.

As of **July 25, 2019**, all claims for ACH-Olmesartan HCTZ 40 mg/25 mg Tablet (DIN 02468964), available direct through the manufacturer, will be adjudicated to the price published in the most recent *ABCDPL* until further notice. The *ABCDPL* is available online at ab.bluecross.ca/providers/pharmacy-home.html.

If this situation continues to be a long-term matter, then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

... continued from previous page

Removal of temporary benefit from the ADBL

Due to the shortage of pms-Sulfasalazine 500 mg Enteric-Coated Tablet (DIN 00598488) and pms-Sulfasalazine 500 mg Tablet (DIN 00598461) manufactured by Pharmascience Inc., Salazopyrin En-Tabs 500 mg Enteric-Coated Tablet (DIN 02064472) manufactured by Pfizer Canada ULC was added as a temporary benefit for the ADBL.

Pharmascience Inc. has advised Alberta Blue Cross that the shortage of pms-Sulfasalazine 500 mg Enteric-Coated Tablet (DIN 00598488) and pms-Sulfasalazine 500 mg Tablet (DIN 00598461) have been resolved.

As a result, Salazopyrin En-Tabs 500 mg Enteric-Coated Tablet (DIN 02064472) will no longer be considered a temporary benefit for the ADBL after **August 26, 2019**.

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)

FAX 780-498-8406 (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit** ab.bluecross.ca/providers/pharmacy-home.php



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.809 2019/08

